ARS Pharmaceuticals, Inc. (SPRY)
Healthcare · NGM
Fundamentals
Valuation and ratings
ARS Pharmaceuticals, Inc. trades at USD5.94, which is 53% above the USD2.80 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 33 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
SPRY earnings and analyst estimates
Recommendation mix, 4 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
SPRY passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$48.04M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$14.24M · 0.0% of book
- Daniel Loeb, Third Point LLC$8.03M · 0.4% of book
- Marshall Wace, MARSHALL WACE, LLP$843.2K · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$207.8K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is ARS Pharmaceuticals, Inc. (SPRY) undervalued?
Against our discounted cash flow estimate of USD2.80, SPRY at USD5.94 is 53% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own SPRY?
6 of the institutions we track reported a position in SPRY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does SPRY report earnings next?
ARS Pharmaceuticals, Inc. is scheduled to report on 13 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for SPRY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.